Key TakeawaysBiogen shares rose 5% today after BofA raised its price target to $244 from $219 and kept a Neutral rating. BofA’s new target is close to the $247 consensus target, which has climbed 43% ...
JPMorgan analyst Chris Schott raises Biogen (BIIB) price target to $300 from $210, citing felzartamab and litifilimab ...
Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock ...
Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline ...
Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, ...
If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...
Biogen (BIIB) narrowly topped Wall Street's fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri. But Tysabri's victory lap could be ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Shares of biotech company Biogen (NASDAQ: BIIB) ...
Biogen shares rose 2.1% in Monday’s premarket trading after JPMorgan upgraded the stock to overweight from neutral, citing an ...
Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results